Isolation of bone marrow fraction rich in connective tissue growth components and the use thereof to promote connective tissue formation

• US 20050130301A1
• Filed: 07/08/2004
• Published: 06/16/2005
• Est. Priority Date: 07/09/2003
• Status: Abandoned Application

• Current Assignee: Jeffrey Marx, William F. Mckay
• Original Assignee: Jeffrey Marx, William F. Mckay
• Inventors: McKay, William F., Marx, Jeffrey
• Application Number:
  US10/887,275
• Publication Number:
  US 20050130301A1
• Time in Patent Office: Days
• US Class Current: 435/372
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/1875 Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: A61L 2430/02 for reconstruction of bones; weight-bearing implants
• CPC Class Codes: A61L 2430/06 for cartilage reconstruction, e.g. meniscus
• CPC Class Codes: A61L 27/3608 Bone, e.g. demineralised bone matrix [DBM], bone powder
• CPC Class Codes: A61L 27/3616 Blood, e.g. platelet-rich plasma
• CPC Class Codes: A61L 27/3691 characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
• CPC Class Codes: A61L 27/38 containing added animal cells organs or tissue containing native cells A61L27/36
• CPC Class Codes: A61L 27/48 with macromolecular fillers
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A bone marrow isolate rich in one or more connective tissue growth components, methods of forming the isolate, and methods of promoting connective tissue growth using the isolate are described. A biological sample comprising bone marrow is centrifuged to separate the sample into fractions including a fraction rich in connective tissue growth components. The fraction rich in connective tissue growth components is then isolated from the separated sample. The isolate can be used directly or combined with a carrier and implanted into a patient at a tissue (e.g., bone) defect site. The biological sample can comprise bone marrow and whole blood. The isolate can be modified (e.g., by transfection with a nucleic acid encoding an osteoinductive polypeptide operably linked to a promoter) prior to application to the tissue defect site. The isolate can be made and applied to the tissue defect site in a single procedure (i.e., intraoperatively).

Claims

1. A method for obtaining a bone marrow fraction, comprising:

a) centrifuging a biological sample including bone marrow and whole blood to provide a separation of components of the sample based on density, said separation providing the following fractions in decreasing order of density;

(i) a fraction rich in blood cells;

(ii) a buffy coat fraction;

(iii) a platelet rich fraction; and

(iv) a platelet poor fraction; and

b) isolating the buffy coat fraction alone or in combination with all or part of the platelet rich fraction to form an isolate rich in connective tissue growth promoting components.

2. The method of claim 1, wherein:

said whole blood and bone marrow are from the same mammalian source.

3. The method of claim 2, wherein:

said mammalian source is a human.

4. The method of claim 1, also comprising combining said isolate rich in connective tissue growth promoting components with a carrier.

5. The method of claim 1, wherein said isolate rich in connective tissue growth promoting components comprises mesenchymal stem cells.

6. The method of claim 1, wherein said whole blood is peripheral blood.

7. The method of claim 1, also comprising:

harvesting said bone marrow from a patient during a surgical procedure.

8. The method of claim 7, wherein:

said centrifuging and isolating are conducted intraoperatively with said surgical procedure.

9. The method of claim 1, wherein said biological sample consists essentially of an anticoagulated mixture of bone marrow and whole blood.

10. The method of claim 1, wherein:

said biological sample centrifuged in the absence of any synthetic density gradient material.

11. The method of claim 1, wherein:

said centrifuging provides a platelet yield of at least about 2.

12. The method of claim 1, wherein:

said isolate rich in connective tissue growth components has a hematocrit content of less than 50% by volume.

13. The method of claim 1, wherein:

said isolate rich in connective tissue growth components has a platelet concentration greater than 4 times that of said biological sample, and a hematocrit content of less than about 12.5% by volume.

14. A method for treating a patient, comprising:

obtaining an isolate including a bone marrow fraction having components that promote connective tissue formation; and

implanting said isolate into a patient at a tissue defect site;

wherein said obtaining is performed intraoperatively with said implanting.

15. The method of claim 14, wherein:

said bone marrow fraction is autologous to the patient.

16. The method of claim 14, wherein:

said obtaining comprises centrifuging a biological sample including bone marrow.

17. The method of claim 15, wherein:

said obtaining includes harvesting bone marrow from the patient, centrifuging a biological sample comprising said bone marrow, and collecting said isolate.

18. The method of claim 17, wherein:

said biological sample also comprises whole blood.

19. The method of claim 18, wherein:

said whole blood is peripheral blood of the patient.

20. The method of claim 19, wherein:

said isolate has a platelet concentration greater than about 2 times that of said biological sample.

21. The method of claim 19, wherein:

said isolate has a hematocrit content of less than about 12.5% by volume.

22. The method of claim 14, wherein:

said implanting is at a bone defect site.

23. The method of claim 22, also comprising:

contacting said isolate with an osteogenic protein prior to, during, or after said implanting.

24. The method of claim 23, wherein:

said osteogenic protein is a bone morphogenic protein (BMP).

25. The method of claim 24, wherein said BMP is BMP-2 or BMP-7.

26. The method of claim 14, wherein:

said implanting is at a cartilage defect site.

27. The method of claim 17, wherein:

said biological sample is centrifuged in the absence of any synthetic density gradient material.

28. The method of claim 19, wherein:

said biological sample consists essentially of an anticoagulated mixture of bone marrow and peripheral blood of the patient.

29. The method of claim 14, also comprising:

combining said isolate with a carrier prior to said implanting.

30. The method of claim 29, wherein:

said carrier is resorbable.

31. The method of claim 30, wherein:

said carrier includes a dimensionally-stable porous matrix material.

32. The method of claim 31, wherein:

said porous matrix material comprises a natural or synthetic polymer.

33. The method of claim 31, wherein:

said porous matrix material comprises a member selected from the group consisting of collagen, gelatin, hyaluronic acid, carboxymethyl cellulose, and synthetic polymers.

34. The method of claim 33, wherein:

said porous matrix material comprises collagen.

35. The method of claim 32, wherein said carrier includes particulate mineral embedded in said porous matrix material.

36. The method of claim 30, wherein:

said carrier is a non-dimensionally-stable carrier.

37. The method of claim 36, wherein;

said carrier is a paste or putty.

38. The method of claim 36, wherein:

said carrier comprises an organic material selected from the group consisting of collagen, gelatin, hyaluronic acid, carboxymethyl cellulose, proteoglycans, glycosaminoglycans, and synthetic polymers.

39. The method of claim 38, wherein:

said carrier includes collagen or gelatin.

40. The method of claim 37, wherein:

said carrier includes particulate mineral in admixture with said organic material.

41. An implant composition, comprising:

an isolate material containing an uncultured bone marrow fraction including tissue growth promoting components, in combination with a biocompatible carrier.

42. The implant composition of claim 41, wherein:

said carrier provides a resorbable scaffold for tissue growth.

43. The implant composition of claim 41, wherein:

said isolate material has been obtained by centrifuging a biological sample including bone marrow and collecting said bone marrow fraction including tissue growth promoting components.

44. The implant composition of claim 41, wherein:

said isolate also comprises peripheral blood components.

45. The implant composition of claim 43, wherein:

said biological sample also includes peripheral blood.

46. The implant composition of claim 42, wherein:

said carrier comprises collagen.

47. The implant composition of claim 45, wherein:

said isolate material has a hematocrit content of less than about 12.5% by volume.

48. The implant composition of claim 41, wherein said tissue growth promoting components include mesenchymal stem cells.

49. A method for treating a patient, comprising:

providing a biological sample including tissue from a bone marrow source of the patient, said sample including tissue growth promoting components;

centrifuging the biological sample to separate the sample into fractions based on density, said fractions including a fraction rich in said tissue growth promoting components;

isolating said fraction rich in tissue growth promoting components;

implanting said fraction rich in tissue growth promoting components into the patient; and

wherein said centrifuging, and isolating are performed intraoperatively with said implanting.

50. The method of claim 49, wherein:

said centrifuging and isolating are effective to enrich said fraction in said growth promoting components relative to said biological sample.

52. The method of claim 49, wherein said growth promoting components include cells, and also comprising genetically modifying said cells.

53. The method of claim 49, wherein said biological sample also comprises whole blood.

54. The method of claim 53, wherein said whole blood is peripheral blood.

55. The method of claim 49, wherein:

said tissue is obtained from said bone marrow source by aspiration.

56. The method of claim 55, wherein:

said tissue is aspirated from an iliac crest of the patient.

57. The method of claim 49, wherein:

said biological sample is centrifuged in the absence of any synthetic density gradient material.

58. A method for obtaining an isolate material comprising tissue growth promoting components, comprising:

harvesting tissue from a bone marrow source of a mammal, said tissue including tissue growth promoting components;

forming an admixture by combining said tissue with whole blood of the mammal;

centrifuging a biological sample including said admixture so as to separate the biological sample into fractions based on density, said fractions including a fraction rich in said tissue growth promoting components; and

isolating said fraction rich in said tissue growth promoting components.

59. A method for obtaining a bone marrow fraction rich in connective tissue growth promoting components, the method comprising:

centrifuging a biological sample comprising bone marrow to separate components of the sample into fractions based on density, said fractions including a fraction rich in tissue promoting components; and

isolating said fraction rich in tissue growth promoting components.

60. A method for preparing a medical implant material for delivery, the method comprising:

(a) centrifuging a biological sample including a bone marrow material under conditions effective to separate a fraction including bone marrow components that promote tissue growth; and

(b) loading the fraction into a device for delivering the fraction to a patient without washing the fraction.

61. A method for preparing a medical implant material for delivery, the method comprising:

(a) centrifuging a biological sample including a bone marrow material under conditions effective to separate a fraction including bone marrow components that promote tissue growth; and

(b) loading the fraction into a device for delivering the fraction to a patient without culturing the fraction.

62. A medical combination comprising an isolated, uncultured bone marrow fraction enriched in components that promote tissue growth, in combination with a device for delivering the material to a patient.